Xglip M 500mg/20mg Tablet

Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, further contributing to blood glucose regulation. The combined formulation offers complementary mechanisms to achieve improved glycemic control in patients inadequately controlled on monotherapy or lifestyle modifications alone.

Xglip M is typically administered once daily with meals to enhance gastrointestinal tolerability and optimize absorption. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose, renal function, and potential adverse effects is recommended. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, or abdominal discomfort, and rare but serious adverse reactions like lactic acidosis should be promptly addressed.

Xglip M 500mg/20mg Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular medical follow-up.